The acquisition aims to strengthen Medicover's laboratory diagnostic business in CEE.

The acquired operations generated €48 million in revenue in 2024 and employ approximately 675 staff. 

They consist of 25 laboratories and 80 blood-drawing points, servicing the general public, specialist doctors, and hospital clients with routine and advanced testing, including human genetics.

Medicover will finance the acquisition from its current committed loan facilities, and the transaction is expected to be earnings per share (EPS) accretive from consolidation. 

“This acquisition will be strongly synergistic in Romania and Turkey, while expanding our advanced testing distribution and reach in the entire region,” said Fredrik Rågmark, CEO of Medicover. “In addition, the acquisition will enable increased operational efficiency and shift advanced tests to other laboratories within the Diagnostic Services network – reflecting our strategy to capture the full potential of our fee-for-service model”.

In 2024, Medicover had revenues of €2 billion and more than 47,000 employees.